Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Identifying PEGylation Sites in Neulasta and a Biosimilar Candidate Using Mass Spectrometry | Contract Pharma

What are you searching for?

Sign in
Sponsored Content

Identifying PEGylation Sites in Neulasta and a Biosimilar Candidate Using Mass Spectrometry

In the development of biosimilar products to Neulasta, it is essential to determine the intact molecular mass and confirm precise PEGylation sites.

Released By Bora Biologics

Abstract
In the development of biosimilar products to Neulasta, it is essential to determine the intact molecular mass and confirm precise PEGylation sites. In this study, we applied a combination of techniques, including post-column addition of triethylamine in reversed-phase liquid chromatography–mass spectrometry (RPLC-MS) to determine the intact molecular mass, and in-source fragmentation (ISF) and higher-energy collision dissociation–tandem mass spectrometry (HCD-MS/MS) to identify the PEGylation site. Click here to read more >>>

Request more information from Bora Biologics

Request more information from Bora Biologics

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters